Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions

Antonio Colombo, Janusz Drzewiecki, Adrian Banning, Eberhard Grube, Karl Hauptmann, Sigmund Silber, Dariusz Dudek, Stephen Fort, Francois Schiele, Krysztof Zmudka, Giulio Guagliumi, Mary E. Russell

Research output: Contribution to journalArticle

934 Citations (Scopus)

Abstract

Background - Early clinical studies demonstrated the feasibility of local paclitaxel delivery in reducing restenosis after treatment of de novo coronary lesions in small patient populations. Methods and Results - We conducted a randomized, double-blind trial of 536 patients at 38 medical centers evaluating slow-release (SR) and moderate-release (MR) formulations of a polymer-based paclitaxel-eluting stent (TAXUS) for revascularization of single, primary lesions in native coronary arteries. Cohort I compared TAXUS-SR with control stents, and Cohort II compared TAXUS-MR with a second control group. The primary end point was 6-month percent in-stent net volume obstruction measured by intravascular ultrasound. Secondary end points were 6-month angiographic restenosis and 6- and 12-month incidence of major adverse cardiac events, a composite of cardiac death, myocardial infarction, and repeat revascularization. At 6 months, percent net volume obstruction within the stent was significantly lower for TAXUS stents (7.9% SR and 7.8% MR) than for respective controls (23. 2% and 20.5%; P

Original languageEnglish
Pages (from-to)788-794
Number of pages7
JournalCirculation
Volume108
Issue number7
DOIs
Publication statusPublished - Aug 19 2003

Fingerprint

Paclitaxel
Stents
Coronary Vessels
Polymers
Myocardial Infarction
Control Groups
Incidence
Population
Therapeutics

Keywords

  • Coronary disease
  • Drugs
  • Restenosis
  • Stents

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. / Colombo, Antonio; Drzewiecki, Janusz; Banning, Adrian; Grube, Eberhard; Hauptmann, Karl; Silber, Sigmund; Dudek, Dariusz; Fort, Stephen; Schiele, Francois; Zmudka, Krysztof; Guagliumi, Giulio; Russell, Mary E.

In: Circulation, Vol. 108, No. 7, 19.08.2003, p. 788-794.

Research output: Contribution to journalArticle

Colombo, A, Drzewiecki, J, Banning, A, Grube, E, Hauptmann, K, Silber, S, Dudek, D, Fort, S, Schiele, F, Zmudka, K, Guagliumi, G & Russell, ME 2003, 'Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions', Circulation, vol. 108, no. 7, pp. 788-794. https://doi.org/10.1161/01.CIR.0000086926.62288.A6
Colombo, Antonio ; Drzewiecki, Janusz ; Banning, Adrian ; Grube, Eberhard ; Hauptmann, Karl ; Silber, Sigmund ; Dudek, Dariusz ; Fort, Stephen ; Schiele, Francois ; Zmudka, Krysztof ; Guagliumi, Giulio ; Russell, Mary E. / Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. In: Circulation. 2003 ; Vol. 108, No. 7. pp. 788-794.
@article{64f0bbee902e437596315ed8b3d7c764,
title = "Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions",
abstract = "Background - Early clinical studies demonstrated the feasibility of local paclitaxel delivery in reducing restenosis after treatment of de novo coronary lesions in small patient populations. Methods and Results - We conducted a randomized, double-blind trial of 536 patients at 38 medical centers evaluating slow-release (SR) and moderate-release (MR) formulations of a polymer-based paclitaxel-eluting stent (TAXUS) for revascularization of single, primary lesions in native coronary arteries. Cohort I compared TAXUS-SR with control stents, and Cohort II compared TAXUS-MR with a second control group. The primary end point was 6-month percent in-stent net volume obstruction measured by intravascular ultrasound. Secondary end points were 6-month angiographic restenosis and 6- and 12-month incidence of major adverse cardiac events, a composite of cardiac death, myocardial infarction, and repeat revascularization. At 6 months, percent net volume obstruction within the stent was significantly lower for TAXUS stents (7.9{\%} SR and 7.8{\%} MR) than for respective controls (23. 2{\%} and 20.5{\%}; P",
keywords = "Coronary disease, Drugs, Restenosis, Stents",
author = "Antonio Colombo and Janusz Drzewiecki and Adrian Banning and Eberhard Grube and Karl Hauptmann and Sigmund Silber and Dariusz Dudek and Stephen Fort and Francois Schiele and Krysztof Zmudka and Giulio Guagliumi and Russell, {Mary E.}",
year = "2003",
month = "8",
day = "19",
doi = "10.1161/01.CIR.0000086926.62288.A6",
language = "English",
volume = "108",
pages = "788--794",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions

AU - Colombo, Antonio

AU - Drzewiecki, Janusz

AU - Banning, Adrian

AU - Grube, Eberhard

AU - Hauptmann, Karl

AU - Silber, Sigmund

AU - Dudek, Dariusz

AU - Fort, Stephen

AU - Schiele, Francois

AU - Zmudka, Krysztof

AU - Guagliumi, Giulio

AU - Russell, Mary E.

PY - 2003/8/19

Y1 - 2003/8/19

N2 - Background - Early clinical studies demonstrated the feasibility of local paclitaxel delivery in reducing restenosis after treatment of de novo coronary lesions in small patient populations. Methods and Results - We conducted a randomized, double-blind trial of 536 patients at 38 medical centers evaluating slow-release (SR) and moderate-release (MR) formulations of a polymer-based paclitaxel-eluting stent (TAXUS) for revascularization of single, primary lesions in native coronary arteries. Cohort I compared TAXUS-SR with control stents, and Cohort II compared TAXUS-MR with a second control group. The primary end point was 6-month percent in-stent net volume obstruction measured by intravascular ultrasound. Secondary end points were 6-month angiographic restenosis and 6- and 12-month incidence of major adverse cardiac events, a composite of cardiac death, myocardial infarction, and repeat revascularization. At 6 months, percent net volume obstruction within the stent was significantly lower for TAXUS stents (7.9% SR and 7.8% MR) than for respective controls (23. 2% and 20.5%; P

AB - Background - Early clinical studies demonstrated the feasibility of local paclitaxel delivery in reducing restenosis after treatment of de novo coronary lesions in small patient populations. Methods and Results - We conducted a randomized, double-blind trial of 536 patients at 38 medical centers evaluating slow-release (SR) and moderate-release (MR) formulations of a polymer-based paclitaxel-eluting stent (TAXUS) for revascularization of single, primary lesions in native coronary arteries. Cohort I compared TAXUS-SR with control stents, and Cohort II compared TAXUS-MR with a second control group. The primary end point was 6-month percent in-stent net volume obstruction measured by intravascular ultrasound. Secondary end points were 6-month angiographic restenosis and 6- and 12-month incidence of major adverse cardiac events, a composite of cardiac death, myocardial infarction, and repeat revascularization. At 6 months, percent net volume obstruction within the stent was significantly lower for TAXUS stents (7.9% SR and 7.8% MR) than for respective controls (23. 2% and 20.5%; P

KW - Coronary disease

KW - Drugs

KW - Restenosis

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=0042388295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042388295&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000086926.62288.A6

DO - 10.1161/01.CIR.0000086926.62288.A6

M3 - Article

C2 - 12900339

AN - SCOPUS:0042388295

VL - 108

SP - 788

EP - 794

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 7

ER -